Grading Liposarcomas with PET using [18F]FDG

Adler, Lee P.; Blair, Henry F.; Williams, Ronald P.; Pathria, Mini N.; Makley, John T.; Joyce, Michael; Al‐Kaisi, Nadia; Miraldi, Floro

doi:10.1097/00004728-199011000-00017

Cited by 67 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the brain, a correlation between the grade of the turnout and the extent of FDG uptake was noted in these patients. This observation was confirmed by Adler et al [37] in five patients with liposarcoma of the thigh. DUR averaged 1.38 in low-grade and 2.45 in high-grade tumours, suggesting a role of FDG in this metabolic distinction.…”

Section: Musculoskeletal Neoplasmssupporting

confidence: 66%

“…A positive correlation between FDG uptake and the tumour grade has been reported in several tumour types including cerebral gliomas [33], liver tumours [34], nonHodgkin's lymphomas [35,36] and some musculoskeletal tumour types [37,38]. The relationship between tumour grade and uptake is, however, less marked in pulmonary tumours [7].…”

Section: Biological Characteristics Of 18-fdgmentioning

confidence: 99%

See 1 more Smart Citation

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

Section: Musculoskeletal Neoplasmssupporting

confidence: 66%

Section: Biological Characteristics Of 18-fdgmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

show abstract

“…20 It can detect STS and give an indication of grade. [21][22][23][24][25] There is limited information on its use in the early detection of local recurrence and metastases after primary surgical treatment of STS. FDG PET has the potential advantage of identifying both complications by a single procedure, and we have tried to evaluate this.…”

mentioning

confidence: 99%

Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas

Lucas

OʼDoherty

Wong

et al. 1998

The Journal of Bone and Joint Surgery. British volume

View full text Add to dashboard Cite

We performed a retrospective analysis to evaluate the ability of whole-body 18 F-fluorodeoxyglucose positron emission tomography (FDG PET) to identify local recurrence and pulmonary metastases in patients with soft-tissue tumours after treatment. We compared the results of FDG PET with those of MRI for the detection of local recurrence, and with CT of the chest for pulmonary metastases.We assessed 62 patients of mean age 51 years, who had 15 types of soft-tissue sarcoma, after a mean follow-up of 3 years 2 months. For the detection of local disease, 71 comparisons showed that the sensitivity and specificity of FDG PET were 73.7% and 94.3%, respectively; there were 14 true-positive and five false-negative results. MRI had a sensitivity and specificity of 88.2% and 96.0% respectively. For the identification of lung metastases, 70 comparisons showed that the sensitivity and specificity of FDG PET were 86.7% and 100%, with 13 true-positive results and two false-negative results. CT of the chest had a sensitivity and specificity of 100% and 96.4%. Thirteen other sites of metastases were identified by FDG PET.FDG PET can identify both local and distant recurrence of tumour as a one-step procedure and will detect other metastases. It seems that all three methods of imaging are needed to define accurately the extent of disease, both at initial staging and during follow-up. and 23% of patients will have metastases, the lung being the most common site with one-third of secondary tumours. Deposits in bone, liver, and brain comprise about 40%; the others are found in the regional lymph nodes, retroperitoneum and soft tissues. 3,4After treatment of the primary tumour between 30% and 35% of patients will develop recurrence either locally or at a distant site. 5,6 Of these patients, between 15% and 47% will develop a local recurrence, depending on the margins achieved at surgical resection. Isolated metastases are seen in the lung in 38% to 64%, and from 28% to 34% will develop metastases at multiple sites. 5-7The optimal management of these tumours depends on the site, size and grade of the local growth and accurate staging of the disease when first seen. The site and size are best determined by MRI, [8][9][10] but the accurate diagnosis of distant metastases is confounded by the wide distribution of potential sites. The detection of local recurrence is hampered by difficulty in differentiating between recurrence, the changes after operation, and the effect of any radiotherapy. Local recurrence is best assessed using MRI with gadolinium contrast enhancement; regular clinical examination alone is insensitive. MRI has a sensitivity of 80% to 85% for the detection of local recurrence, better than CT which has a sensitivity of 57% to 70%. [11][12][13][14] Ultrasound has a similar sensitivity to MRI for the detection of local recurrence, but depends very much on the proficiency of the operator. 10,12 A variety of radionucleide methods has been tried with varying success.14,15Lung metastases can be identified using CT, but other

show abstract

“…2 shows that the FDG uptake can be variable within a tumor. Therefore, PET scanning may provide important information about metabolic activity and may be useful in combination with MRI/CT scanning for guiding a biopsy and avoiding sampling errors (29,30). In The Netherlands, the costs of an FDG-PET study for detection of a recurrent neoplasm currently amount to the equivalent of approximately US$820, whereas MRI costs approximately $680 and CT $280.…”

Section: Discussionmentioning

confidence: 99%

Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose

Kole¹,

Nieweg

vanGinkel³

et al. 1997

Annals of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Grading Liposarcomas with PET using [18F]FDG

Cited by 67 publications

References 0 publications

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas

Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose

Contact Info

Product

Resources

About